Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants with Systemic Lupus Er… Ended

2022-502632-39-00 Systemic Lupus Erythematosus (SLE) 2023-10-11
ELVN-002 in Solid Tumors with a HER2 Genetic Alteration Ended

2022-502695-23-00 Phase 1a Monotherapy Dose Escalation and Exploration: 2023-09-27
Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA Ended

2024-517045-14-00 Mucopolysaccharidosis type IIIA (MPS IIIA) 2023-09-26
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9 Ended

2022-500706-18-01 Influenza prophylaxis 2023-09-11
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-20… Ended

2022-500758-41-00 Amyotrophic lateral sclerosis 2023-08-15
A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors. Ended

2023-509568-81-00 Advanced Breast Cancer and Other Solid Tumors 2023-07-27
Phase I study of AZD9592 in solid tumors Ended

2022-501570-18-00 Recurrent or metastatic Head and NeckSquamous Cell Carc 2023-07-18
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115. Ended

2023-505643-39-00 Spinal muscular atrophy 2023-07-17
A Study of EOS301984 in Adult Participants with Advanced Solid Tumors Ended

2023-503844-14-00 Advanced Solid Tumors 2023-06-13
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with ritu… Ended

2024-512390-27-00 Relapsed/refractory CD20 positive B-cell Non-Hodgkin's 2023-06-09
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Parti… Ended

2023-509414-11-00 Neoplasms 2023-05-24
A First-In-Human Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer Ended

2024-512296-13-00 colorectal cancer 2023-04-03
Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides … Ended

2024-517580-23-00 Sarcoma 2023-03-07
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult P… Ended

2024-510995-18-00 Advanced Solid Tumors 2023-03-01
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut… Ended

2024-511548-19-00 Pancreatic Ductal Adenocarcinoma 2022-12-13
A clinical study to determine the dose and assess safety and efficacy of radioimmuntherapy in patients with glioblastoma, where Lutetium 177… Ended

2024-513638-39-00 Surgically treated high grade glioma after concomitant 2022-10-17
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL Ended

2023-504187-42-00 Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leuk 2022-09-12
Live Attenuated Rift Valley Fever Vaccine for Single Shot Administration (LARISSA) Ended

2022-501460-17-00 Rift Valley fever (RVF) infection 2022-07-26
Clinical trial of MK-1484 given alone and with pembrolizumab in adults with solid tumors Ended

2023-505067-36-00 Advanced or Metastatic Solid Tumors 2022-06-22
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combinatio… Ended

2023-506854-19-00 Solid Tumors 2022-05-19
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Ca… Ended

2023-506265-65-00 Localized Bladder Cancer 2022-04-07
Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Ended

2024-515848-23-00 Metastatic or Locally Advanced Unresectable Solid Tumor 2022-03-18
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I… Ended

2024-515617-18-00 Advanced clear cell renal cell carcinoma (ccRCC), non-c 2022-02-14
FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS Ended

2023-504605-36-00 Dose escalation cohort: advanced and/or metastatic canc 2022-01-21